Pfizer BioNTech seek US FDA Emergency Use Authorization for Omicron BA.4/BA.5-adapted bivalent vaccine booster in children 5 through 11 years of age

Pfizer Inc. and BioNTech SE announced they have completed a submission to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-